Skip to main content

Table 1 Patient demographics and baseline disease characteristics

From: Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures

Characteristic

PBO (N = 230)

GMB 120 mg (N = 232)

Age, years, mean (SD)

45.7 (12.3)

45.9 (11.3)

Female, n (%)

202 (87.8)

195 (84.1)

Race (N = 223), n (%)

 White

182 (81.6)

183 (81.7)

 Asian

35 (15.7)

37 (16.5)

 Black or African American

2 (0.9)

3 (1.3)

Duration of migraine illness, years, mean (SD)

23.8 (13.9)

22.7 (13.2)

Monthly migraine headache days, mean (SD)

13.0 (5.7)

13.4 (6.1)

Weekly migraine headache days,a mean (SD)

3.0 (1.3)

3.1 (1.4)

Total number of failed individual preventive medications in past 10 years,b mean (SD)

3.3 (1.7)

3.3 (1.6)

  1. PBO Placebo. GMB Galcanezumab. SD Standard deviation. N Number of intent-to-treat patients. n Number of patients within each specific category
  2. aBased on baseline monthly migraine headache days and normalized to a weekly range
  3. bBased on any medications taken for migraine prevention in the past 10 years; not limited to the qualifying standard-of care treatments specified in the inclusion criteria. Medication failure was defined as discontinuation due to no response, inadequate response, or safety/tolerability event. Contraindications did not count as medication failures